## II. REMARKS

Claims 14, 24, 28, 29, 30, 44, 46, 61, 63, 64, 72, 74-76, 79, 80, 83 and 84 have been amended to place into better form for issuance and to address minor section 112 second paragraph concerns. Claims 11-15, 18-20, 22-25, 28-30, 44, 46, 58-65, 72-76, 79-89, 91 and 92 are pending.

Most of the amendments are to address antecedent basis concerns with respect to the term "composition" and "phospholipid." Additionally, claims previously employing the phrase "complementary to at least 8 consecutive bases of the translation initiation site of Bcl-2 mRNA" or similar language have been revised as suggested by the Examiner to recite "that hybridizes to a Bcl-2-encoding polynucleotide under intracellular conditions."

Claim 73 has been amended to correct the dependency.

To address the Examiner's concerns regarding the "consisting essentially of" claims that depend from claims directed to both neutral and charged phospholipids, claims 76, 80, 83 and 74 have been amended to refer to both neutral and charged lipids.

Applicants appreciate the Examiner's efforts in reviewing the claims for informalities, and have accordingly submitted minor, formalistic amendments that are believed to place the present claims in condition for allowance. In view of this, Applicants respectfully request that the present claims be passed to allowance. Should the Examiner have any comments or questions with regard to any statements contained herein, or any suggestions as to claim modification, the Examiner is respectfully requested to contact the Applicants' representative listed below at (512) 536-3055.

Please date-stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

David L. Parker Reg. No. 32,165 Attorney for Applicants

FULBRIGHT & JAWORSKI, L.L.P. 600 Congress Ave., Suite 2400 Austin, Texas 78701 (512) 536-3055 (512) 536-4598 (facsimile)

Date: August 11, 2004